Genmab — Maj 2014
-
efter 2200 i aften
-
23
-
men nogen gange åbner de kanalerne lidt før
men genmab kommer selv med en pressemeddelelse -
men derfor skal der nok være nogle af os nørder der finder dataene selv inden genmab sender dem ud
-
Der går et par dage før de nye aktier bliver registreret hos Erhvervsstyrelsen og kan sælges
-
så nok først i næste uge du vil se salgene. Så må vi håbe ASCO dataene i aften giver købspres imorgen. Nogen som har link til hvor de bliver frigivet?
-
-
Så er de online http://abstracts.asco.org/144/CatView_144_B.html
-
-
Sanofis kombo data med Revlimid er ikke mega stærke: The ORR (≥ PR), according to IMWG criteria, among 12 evaluable pts was 58 %. Responses occurred at each DL of 3mg/kg (1PR), 5mg/kg (1PR, 1 VGPR) and 10 mg/kg (1PR, 3 VGPR).
-
pt. ingen CR !!!!!!!
-
DARA+LEN+DEX has favorable safety profile with manageable toxicities in relapsed and RR MM. Encouraging early activity is seen with marked reduction in M-protein and 8/11 patients (72%) achieving PR or better. Part 2 data will be presented
-
SAR overall response rate er ikke mega god. http://abstracts.asco.org/144/AbstView_144_129808.html kun 33% ORR i patienter behandlet med over 10 mg. de har dog 11% CR i de patienter. men stadigvæk.. Dara har noget højere ORR dog lavere CR
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind